AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
Log in

NASDAQ:NCNANuCana Stock Price, Forecast & News

$5.45
+0.08 (+1.49 %)
(As of 07/2/2020 02:44 PM ET)
Add
Compare
Today's Range
$5.45
Now: $5.45
$5.45
50-Day Range
$5.45
MA: $5.96
$7.37
52-Week Range
$3.81
Now: $5.45
$11.14
Volume1 shs
Average Volume60,214 shs
Market Capitalization$177.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More
NuCana logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NCNA
CUSIPN/A
Phone44-0-13-1357-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Employees29
Market Cap$177.02 million
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

NuCana (NASDAQ:NCNA) Frequently Asked Questions

How has NuCana's stock been impacted by COVID-19 (Coronavirus)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NCNA shares have decreased by 14.0% and is now trading at $5.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NuCana?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NuCana.

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for NuCana.

How were NuCana's earnings last quarter?

NuCana PLC (NASDAQ:NCNA) posted its quarterly earnings results on Tuesday, May, 19th. The company reported ($12.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($18.20) by $6.20. View NuCana's earnings history.

What price target have analysts set for NCNA?

5 brokers have issued 1-year price targets for NuCana's shares. Their forecasts range from $15.00 to $25.00. On average, they expect NuCana's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 242.5% from the stock's current price. View analysts' price targets for NuCana.

What are Wall Street analysts saying about NuCana stock?

Here are some recent quotes from research analysts about NuCana stock:
  • 1. According to Zacks Investment Research, "NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. " (3/17/2020)
  • 2. HC Wainwright analysts commented, "We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate." (8/19/2019)

Has NuCana been receiving favorable news coverage?

News articles about NCNA stock have trended very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuCana earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about NuCana.

Are investors shorting NuCana?

NuCana saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,470,000 shares, a decline of 5.4% from the May 31st total of 2,610,000 shares. Based on an average daily volume of 93,800 shares, the short-interest ratio is presently 26.3 days. Approximately 8.3% of the company's stock are sold short. View NuCana's Current Options Chain.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 74)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 52)
  • Mr. Donald Munoz, Chief Financial Officer (Age 51)

When did NuCana IPO?

(NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $5.45.

How big of a company is NuCana?

NuCana has a market capitalization of $177.02 million. The company earns $-27,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. NuCana employs 29 workers across the globe.

What is NuCana's official website?

The official website for NuCana is www.nucana.com.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.